Skip to Content

Albendazole Disease Interactions

There are 4 disease interactions with albendazole:

Major

Albendazole (applies to albendazole) myelosuppression

Major Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts

Reversible leukopenia has been reported during albendazole therapy. Rarely, granulocytopenia or pancytopenia have resulted in death. Therapy with albendazole should be administered cautiously in patients with predisposition to myelosuppression. Clinical monitoring of hematopoietic function prior to each cycle of albendazole and every two weeks during therapy is recommended. Albendazole can be continued with a modest, non- progressive decrease in leukocyte count and absolute neutrophil count.

References

  1. "Product Information. Albenza (albendazole)." SmithKline Beecham, Philadelphia, PA.
  2. Fernandez FJ, Rodriguezvidigal FF, Ledesma V, Cabanillas Y, Vagace JM "Aplastic anemia during treatment with albendazole." Am J Hematol 53 (1996): 53-4
Moderate

Albendazole (applies to albendazole) hepatobiliary dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease, Biliary Obstruction

Albendazole is converted to its biologically active metabolite and further metabolized to an inactive form by the liver. Biliary excretion of albendazole is the primary route of elimination and biliary obstruction results in increased albendazole serum concentration and AUC. Metabolism and therapeutic activity may be altered in patients with hepatic impairment. Elevated liver transaminase levels have been reported in 16% of patients receiving albendazole. Therapy with albendazole should be administered cautiously in patients with compromised hepatic function. Clinical monitoring of hepatic function is recommended prior to initiation of each cycle of albendazole and at least every two weeks during therapy. Patients with elevated liver enzyme test results are at increased risk for hepatotoxicity and bone marrow suppression. Discontinue therapy if liver enzymes are significantly increased or if a clinically significant decrease in blood cell counts occur.

References

  1. Marriner SE, Morris DL, Dickson B, Bogan JA "Pharmacokinetics of albendazole in man." Eur J Clin Pharmacol 30 (1986): 705-8
  2. "Product Information. Albenza (albendazole)." SmithKline Beecham, Philadelphia, PA.
  3. Choudhuri G, Prasad RN "Jaundice due to albendazole." Indian J Gastroenterol 7 (1988): 245-6
Moderate

Albendazole (applies to albendazole) neurologic dysfunction

Moderate Potential Hazard, High plausibility. Applicable conditions: Intracranial Hypertension, Seizures

Albendazole therapy of neurocysticercosis can induce an inflammatory response within the CNS that precipitates seizures and cerebral hypertension. Therapy with albendazole for neurocysticercosis should be administered cautiously in patients with or predisposition to seizures. The use of corticosteroids during the first week of therapy to prevent cerebral hypertension and anticonvulsant therapy as required is recommended.

References

  1. "Product Information. Albenza (albendazole)." SmithKline Beecham, Philadelphia, PA.
  2. Cruz I, Cruz ME, Carrasco F, Horton J "Neurocysticercosis: optimal dose treatment with albendazole." J Neurol Sci 133 (1995): 152-4
Moderate

Albendazole (applies to albendazole) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

The pharmacokinetics of albendazole in patients with impaired renal function have not been studied. Caution is advised if used in these patients.

Albendazole drug interactions

There are 96 drug interactions with albendazole

Albendazole alcohol/food interactions

There is 1 alcohol/food interaction with albendazole

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.